Trump administration reclassifies state-licensed medical marijuana from Schedule I to Schedule III, giving dispensaries major tax breaks and easing research barriers in historic federal policy shift.
Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical marijuana from Schedule I to Schedule III, marking a major shift in federal drug policy. The change gives licensed medical marijuana dispensaries significant tax breaks by allowing them to deduct business expenses for the first time, and it eases barriers to researching cannabis. The order does not legalize marijuana at the federal level but sets up an expedited registration system for state-licensed producers and distributors with the Drug Enforcement Administration.
The reclassification legitimizes medical marijuana programs in the 40 states that have adopted them since California became the first in 1996. According to the BBC, marijuana has been classified as Schedule I since 1970, defined as having high potential for abuse and no accepted medical use. The new Schedule III classification puts medical marijuana on par with drugs like Tylenol with codeine, implying moderate to low potential for dependence. Marijuana or products not distributed through state medical programs will remain Schedule I.
Trump ordered his administration in December to work quickly on reclassification, and a new administrative hearing is scheduled for June to consider broader marijuana rescheduling that could benefit recreational markets. The Biden administration had initiated a review in 2022, but the process stalled before completion. Some critics argue legalization has led to stronger cannabis products that need research rather than less strict classification, with cannabis use disorder affecting about 3 in 10 users according to the CDC. The National Organization for the Reform of Marijuana Laws called the move mostly symbolic and continues pushing for full federal legalization.
Editor’s rationale — Major regulatory reclassification of medical marijuana from Schedule I to Schedule III by Acting Attorney General Todd Blanche, representing a structural change in federal drug enforcement policy affecting 40 states' medical marijuana programs and creating permanent tax benefits and research pathways. Nationwide scope with long-term policy implications, verified through official Department of Justice action and direct statements from Trump administration officials.